Back
Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.
Journal article

Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.

  • Koelzer VH Translational Research Unit (TRU), Institute of Pathology, University of Bern, CH-3010 Bern, Switzerland; Clinical Pathology Division, Institute of Pathology, University of Bern, CH-3010 Bern, Switzerland. Electronic address: viktor.koelzer@pathology.unibe.ch.
  • Huber B Institute of Pathology, University of Basel, CH-4031 Basel, Switzerland.
  • Mele V Institute of Surgical Research and Hospital Management (ICFS) and Department of Biomedicine, University Hospital Basel, University of Basel, CH-4031 Basel, Switzerland.
  • Iezzi G Institute of Surgical Research and Hospital Management (ICFS) and Department of Biomedicine, University Hospital Basel, University of Basel, CH-4031 Basel, Switzerland.
  • Trippel M Translational Research Unit (TRU), Institute of Pathology, University of Bern, CH-3010 Bern, Switzerland; Clinical Pathology Division, Institute of Pathology, University of Bern, CH-3010 Bern, Switzerland.
  • Karamitopoulou E Translational Research Unit (TRU), Institute of Pathology, University of Bern, CH-3010 Bern, Switzerland; Clinical Pathology Division, Institute of Pathology, University of Bern, CH-3010 Bern, Switzerland.
  • Zlobec I Clinical Pathology Division, Institute of Pathology, University of Bern, CH-3010 Bern, Switzerland.
  • Lugli A Translational Research Unit (TRU), Institute of Pathology, University of Bern, CH-3010 Bern, Switzerland; Clinical Pathology Division, Institute of Pathology, University of Bern, CH-3010 Bern, Switzerland.
Show more…
  • 2015-09-10
Published in:
  • Human pathology. - 2015
CD168
Colorectal cancer
Hyaluronan-mediated motility receptor
Prognostic factor
RHAMM
Tumor budding
Adenocarcinoma
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Colorectal Neoplasms
Extracellular Matrix Proteins
Female
Humans
Hyaluronan Receptors
Intestinal Mucosa
Lymphatic Metastasis
Male
Middle Aged
Prognosis
Survival Rate
Tissue Array Analysis
English Expression of the hyaluronan-mediated motility receptor (RHAMM, CD168) predicts adverse clinicopathological features and decreased survival for colorectal cancer (CRC) patients. Using full tissue sections, we investigated the expression of RHAMM in tumor budding cells of 103 primary CRCs to characterize the biological processes driving single-cell invasion and early metastatic dissemination. RHAMM expression in tumor buds was analyzed with clinicopathological data, molecular features and survival. Tumor budding cells at the invasive front of CRC expressed RHAMM in 68% of cases. Detection of RHAMM-positive tumor budding cells was significantly associated with poor survival outcome (P = .0312), independent of TNM stage and adjuvant therapy in multivariate analysis (P = .0201). RHAMM-positive tumor buds were associated with frequent lymphatic invasion (P = .0007), higher tumor grade (P = .0296), and nodal metastasis (P = .0364). Importantly, the prognostic impact of RHAMM expression in tumor buds was maintained independently of the number of tumor buds found in an individual case (P = .0246). No impact of KRAS/BRAF mutation, mismatch repair deficiency and CpG island methylation was observed. RHAMM expression identifies an aggressive subpopulation of tumor budding cells and is an independent adverse prognostic factor for CRC patients. These data support ongoing efforts to develop RHAMM as a target for precision therapy.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/241651
Statistics
Document views: 12 File downloads: